Cargando…
Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
Nonmyeloablative regimens are used for allogeneic hematopoietic cell transplantation (HCT) of older or medically unfit patients, but successful outcome is still hindered by graft-versus-host disease (GVHD), especially in the setting of HLA-mismatched HCT. New GVHD prophylaxis strategies are emerging...
Autores principales: | van der Velden, Walter J. F. M., Choi, Goda, de Witte, Moniek A., van der Meer, Arnold, de Haan, Anton F. J., Blijlevens, Nicole M. A., Huls, Gerwin, Kuball, Jürgen, van Dorp, Suzanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214052/ https://www.ncbi.nlm.nih.gov/pubmed/34148060 http://dx.doi.org/10.1038/s41409-021-01369-9 |
Ejemplares similares
-
Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019) -
What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005) -
Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
por: Wang, Yu, et al.
Publicado: (2019) -
Anti-Thymocyte Globulin (ATG)-Free Nonmyeloablative Haploidentical PBSCT Plus Post-Transplantation Cyclophosphamide Is a Safe and Efficient Treatment Approach for Pediatric Acquired Aplastic Anemia
por: Chen, Rong-Long, et al.
Publicado: (2022) -
P1382: RUXOLITINIB USE IN A REAL WORLD ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE COHORT IN THE NETHERLANDS: A RETROSPECTIVE STUDY
por: Van Der Wagen, L., et al.
Publicado: (2022)